NOVARTIS

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public, Private

Established: 1996-01-01

Employees: 76K

Market Cap: $242.6B

Website: https://www.novartis.com/our-science/novartis-institutes-biomedical-research

Clinical Trials

Efficacy and Safety of Intraseasonal Specific Immunotherapy With Depiquick® Birch

Phase 3

Completed

Conditions: Allergic Rhinoconjunctivitis

Interventions: Drug: Depiquick Birch (DPG103)
Drug: Placebo

First Posted Date: 2013-07-19

Last Posted Date: 2017-03-22

Lead Sponsor: Novartis

Target Recruit Count: 202

Registration Number: NCT01902992

Locations: 🇩🇪
Novartis Investigative Site, Witten, Germany

Immunogenicity, Safety and Tolerability of a Trivalent Subunit Inactivated Vaccine in Healthy Subjects 50 Years and Above

Phase 4

Completed

Conditions: Influenza

Interventions: Biological: Fluvirin(TIVf)
Biological: Agriflu (TIV)

First Posted Date: 2013-06-03

Last Posted Date: 2014-10-01

Lead Sponsor: Novartis

Target Recruit Count: 2902

Registration Number: NCT01867021

Locations: 🇿🇦
Site 33 - TREAD Research , Room 41, 8th Floor, Department of Cardiology, Tygerberg Hospital, Francie van Zijl Drive, Province of the Western Cape, Cape Town, South Africa
🇿🇦
Site 34 - Synopsis Research, Room 8, First floor, Fountain Centre, Belmont Road, Rondebosch, Cape Town, South Africa
🇿🇦
Site 43 - Allergy Diagnostic & Clinical Research Unit, UCT Lung Institute, George Street, Province of the Western Cape, Cape Town, South Africa

and more 22 locations

Retrospective Study of Long-term Survival and Related Factors Among Kidney Transplant Recipients in China

Completed

Conditions: Kidney Transplantation

First Posted Date: 2013-02-22

Last Posted Date: 2014-06-18

Lead Sponsor: Novartis

Target Recruit Count: 1500

Registration Number: NCT01796639

Locations: 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳
Nanfang Hospital, Guangzhou, Guangdong, China
🇨🇳
The Second Xiangya Hospital of Central South University, Changsha, Hunan, China

and more 15 locations

Follow-up Study of Patients Who Experienced Thromboembolic Events in the ENABLE Studies

Completed

Conditions: Hepatitis C

Interventions: Drug: Eltrombopag

First Posted Date: 2012-10-29

Last Posted Date: 2016-04-08

Lead Sponsor: Novartis

Target Recruit Count: 22

Registration Number: NCT01715779

Efficacy and Safety of Diclofenac Potassium 25 mg Tablet Taken Three Times Daily in Subjects With Acute Joint Pain

Phase 4

Completed

Conditions: Ankle Sprain

Interventions: Drug: diclofenac potassium 25 mg tablet
Drug: placebo

First Posted Date: 2012-08-16

Last Posted Date: 2014-04-17

Lead Sponsor: Novartis

Target Recruit Count: 100

Registration Number: NCT01666197

Locations: 🇩🇪
Investigator, Köln, Germany

Warming Sensation Intensity and Acceptability of the Flavour, Local Tolerability of Paracetamol 500 mg + Pseudoephedrine 30 mg Syrup in Patients Suffering a URTI

Phase 3

Completed

Conditions: Upper Respiratory Infections

Interventions: Drug: IFF flavor 316 282, Paracetamol, Pseudoephedrine

First Posted Date: 2012-04-27

Last Posted Date: 2013-08-07

Lead Sponsor: Novartis

Target Recruit Count: 56

Registration Number: NCT01586962

Locations: 🇨🇦
Algorithme Pharma, Montreal, Quebec, Canada

Warming Sensation Intensity and Acceptability of the Flavour, Local Tolerability of Paracetamol 500 mg + Phenylephrine 10mg + Guaifenesin 200 mg Syrup in Patients Suffering a Upper Respiratory Tract Infection (URTI)

Phase 3

Completed

Conditions: Upper Respiratory Infections

Interventions: Drug: IFF flavor 316 282, Paracetamol , Phenylephrine, Guaifenesin

First Posted Date: 2012-04-12

Last Posted Date: 2013-11-11

Lead Sponsor: Novartis

Target Recruit Count: 51

Registration Number: NCT01576809

Locations: 🇨🇦
Algorithme Pharma, Montreal, Quebec, Canada

Pharmacokinetics, Safety and Tolerability of Aliskiren (SPP100) in Patients With End Stage Renal Disease on Hemodialysis and Matched Healthy Subjects

Phase 1

Completed

Conditions: End Stage Renal Disease

Interventions: Drug: Aliskiren

First Posted Date: 2012-04-02

Last Posted Date: 2012-04-02

Lead Sponsor: Novartis

Target Recruit Count: 12

Registration Number: NCT01568775

Locations: 🇩🇪
Charité Universitätsmedizin, Berlin, Germany

Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 75 Years of Age in India

Phase 3

Completed

Conditions: Bacterial Meningitis

Interventions: Biological: Meningococcal ACWY conjugate vaccine

First Posted Date: 2012-03-08

Last Posted Date: 2018-10-09

Lead Sponsor: Novartis

Target Recruit Count: 180

Registration Number: NCT01547715

Locations: 🇮🇳
Osmania Medical College Ethics Commitee, Niloufer Hospital, Hyderabad, Andrapradesh, India
🇮🇳
Padmasree Dr. D.Y Patil medical College, Pune, Maharashtra, India
🇮🇳
Bharati Vidyapeeth University Institutional Ethics Commitee, Katraj, Dhankawadi, India

and more 1 locations

A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults

Phase 3

Completed

Conditions: Meningococcal Meningitis
Typhoid
Japanese Encephalitis
Meningococcal Disease
Yellow Fever
Rabies

Interventions: Biological: Rabies Vaccine
Biological: Typhoid Vi Polysaccharide Vaccine
Biological: Japanese Encephalitis Vaccine
Biological: Yellow Fever Vaccine
Biological: MenACWY-CRM Vaccine

First Posted Date: 2011-11-08

Last Posted Date: 2014-03-11

Lead Sponsor: Novartis

Target Recruit Count: 552

Registration Number: NCT01466387

Locations: 🇨🇿
Centrum ockovani a cestovni mediciny (Vaccination and Travel Medicine Centre) Poliklinika II, Bratri Stefanu 895, Hradec Kralove, Czech Republic
🇩🇪
University of Munich Georgenstr.5, Muenchen, Germany
🇩🇪
Berliner Centrum Fur Reise und Tropenmedizin, Jaegerstrasse 67-69, Berlin, Germany

and more 1 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy